Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, whi